Background
The Centres for Disease Control and Prevention (CDC) hosted the 10th Annual Fungal Disease Awareness Week (FDAW) to highlight the growing threat of multidrug-resistant fungal infections. Scientists warn that pathogens such as Candida auris are increasingly resistant to conventional antifungal drugs, raising concerns over the effectiveness of existing treatments.
About Fungi
- Fungi are eukaryotic, heterotrophic organisms including yeasts, moulds and mushrooms.
- Unlike plants, they lack chlorophyll and obtain nutrients by secreting extracellular enzymes and absorbing organic matter.
- Ecological role: Vital decomposers, recycling nutrients in ecosystems.
- Applications: Food production, biotechnology and pharmaceuticals — e.g., yeast in fermentation and Penicillium in antibiotic production.
- Pathogenic fungi cause fungal infections (mycoses), ranging from superficial diseases (ringworm, nail infections) to severe systemic infections, particularly in immunocompromised individuals.
Emergence of Candida auris
- Originally reported in 2009, this yeast has become a multidrug-resistant pathogen in ICU facilities.
- Causes severe bloodstream infections with a 30-40% mortality rate.
- Studies suggest global warming puts selective pressure on fungi, allowing heat-tolerant variants to survive the human body's 37°C temperature.
Mechanisms of Drug Resistance
- Gene Duplication: Fungi fight azole drugs by making extra copies of the Erg11 gene, increasing production of ergosterol to negate the drug's effect.
- Genetic Mutation: Mutations in the Fks1 gene allow pathogens to survive high doses of echinocandin drugs like caspofungin.
- The Eagle Effect: At exceptionally high drug doses, fungi activate compensatory pathways to produce massive amounts of chitin (the raw material of the fungal cell wall), allowing them to survive treatment paradoxically.
Antifungal Drug Targets
- Azoles and polyenes target ergosterol in the fungal cell membrane.
- Echinocandins target the fungal cell wall.
- India-specific data: Over 90% of Indian C. auris isolates are resistant to azoles, and 30% are resistant to polyenes.
Healthcare Infrastructure Gap
- While 20% of reported hospital infections are fungal, most Indian hospitals lack the capabilities to accurately identify and culture these pathogens.
Alternative Approaches
- Instead of total eradication (which drives rapid evolution), scientists advocate for:
- Combination therapies
- Targeting less critical molecular pathways to stop disease progression without forcing evolutionary resistance.
Comparison: Fungi vs. Bacteria vs. Viruses
| Feature | Fungi | Bacteria | Viruses |
|---|---|---|---|
| Cell Type | Eukaryotic | Prokaryotic | Acellular |
| Cell Structure | Nucleus and membrane-bound organelles | Lack true nucleus and membrane-bound organelles | No cellular structure |
| Genetic Material | DNA | DNA | DNA or RNA |
| Typical Size | Generally larger than bacteria | Smaller than fungi | Smallest of the three |
| Nutrition | Heterotrophic, absorb nutrients from organic matter | Autotrophic or heterotrophic | Cannot obtain nutrients independently |
| Reproduction | Spores, budding or fragmentation | Mainly binary fission | Replicate only inside a host cell |
| Examples | Candida auris, Aspergillus, Penicillium, yeast | E. coli, Mycobacterium tuberculosis | SARS-CoV-2, Influenza, HIV |
| Diseases | Mycoses, ringworm, candidiasis | Tuberculosis, cholera, typhoid | COVID-19, influenza, dengue |
Significance for India
- Antimicrobial resistance (AMR) extends beyond bacteria to fungi — a neglected dimension of India's AMR action plan.
- Weak diagnostic infrastructure in hospitals hampers early detection of fungal infections.
- Climate change-driven fungal adaptation adds a new dimension to health security concerns.
- Highlights the need for antimicrobial stewardship, surveillance networks, and investment in diagnostics and new therapeutics.